PET MRI Study in Patients With Cardiac Sarcoidosis

Status Completed

Clinical Trial Summary

Myocarditis or inflammatory cardiomyopathy refers to inflammation of the heart muscle (the myocardium). Sarcoidosis is a multisystem granulomatous disorder that may involve the heart, causing inflammation, and potentially resulting in complications including arrhythmia and sudden death. The objective of this study is to evaluate the diagnostic and prognostic significance of simultaneous combined 18F-FDG PET and cardiac MRI imaging in the evaluation of inflammatory cardiomyopathies including cardiac sarcoidosis. Combined PET/MRI imaging may allow for detection and quantification of active myocardial inflammation as well as chronic fibrosis and scarring. Results of this study may allow for earlier detection of cardiac inflammation when compared with methods in current clinical use, and may lead to better understanding of the disease processes contributing to adverse outcomes. Elucidation of imaging findings associated with future adverse event risk may impact patient management such as providing an indication for pacemaker or defibrillator implantation, or escalation of medical therapy.

Clinical Trial Description

Myocarditis or inflammatory cardiomyopathy refers to inflammation of the myocardium. Sarcoidosis is a multisystem granulomatous disorder of unknown etiology, which can result in myocardial inflammation. Approximately 5% of patients with sarcoidosis have clinically apparent cardiac involvement, yet autopsy series indicate that cardiac involvement is present in up to 25% of cases. This discrepancy suggests that cardiac sarcoidosis may be under-diagnosed in clinical practice. Recent studies have demonstrated high diagnostic accuracy of both cardiac MRI and 18F-labelled fluoro-2-deoxyglucose (FDG) PET for detection of cardiac involvement. However, cardiac MRI may fail to identify areas of active inflammation even with fluid sensitive T2-weighted sequences. Fasting 18F-FDG positron emission tomography (PET) has been shown to identify early cardiac sarcoidosis with relatively high sensitivity. To date, simultaneous PET/MRI evaluation of cardiac inflammation and sarcoidosis has only been described in limited case reports. The objective of the proposed research is to evaluate the utility of simultaneous PET/MRI imaging in patients with cardiac sarcoidosis and other inflammatory cardiomyopathies. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03356756
Study type	Observational
Source	University Health Network, Toronto
Contact
Status	Completed
Phase
Start date	June 27, 2016
Completion date	February 23, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04008069` - Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis	Phase 2
Recruiting	`NCT02807025` - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases	N/A
Completed	`NCT01615484` - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability	N/A
Completed	`NCT00274352` - A Study of Adalimumab to Treat Sarcoidosis of the Skin	Phase 2
Completed	`NCT00326534` - Rickettsial Genesis to Sarcoidosis in Denmark	N/A
Completed	`NCT00373555` - Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis	N/A
Recruiting	`NCT00470327` - A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Completed	`NCT00512967` - The Occurence of Inflammation and Oxidative Stress in Lung Diseases	N/A
Recruiting	`NCT01745237` - Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
Completed	`NCT00369980` - Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient	N/A
Completed	`NCT00366509` - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Completed	`NCT00379275` - Eye and Immunogenetic Features of Sarcoidosis	N/A
Completed	`NCT06396910` - TB and Sarcoidosis Granuloma
Completed	`NCT04156789` - Obstructive Sleep Apnoea in Sarcoidosis
Recruiting	`NCT02916459` - EBUS-TBNA vs Flex 19G EBUS-TBNA	N/A
Recruiting	`NCT02827734` - Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
Completed	`NCT02546388` - Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis	N/A
Completed	`NCT01687517` - Efficacy and Safety of Influenza Vaccine During Sarcoidosis	Phase 3
Completed	`NCT01139710` - Sarcoidosis-associated Pulmonary Hypertension	N/A
Terminated	`NCT00747461` - Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.